EdaƱo, Eufemia P.
HRN: 22-49-51 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/13/2023
CO-AMOXICLAV 625MG (TAB)
06/13/2023
06/20/2023
ORAL
625mg
TID
CAP HR
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Non-compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes